(MedPage Today) — Loss of copayment assistance for drugs to treat neovascular age-related macular degeneration (nAMD) significantly disrupted patient care, including switching to less costly (and perhaps less effective) therapy, reliance on samples…
Source link : https://www.medpagetoday.com/ophthalmology/generalophthalmology/121974
Author :
Publish date : 2026-06-29 20:00:00
Copyright for syndicated content belongs to the linked Source.
